The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims
BACKGROUND: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder which can affect multiple organs of the body, requiring ongoing disease management and healthcare resource utilization. The economic impact of SLE has not been evaluated in a Medicare population to date. This study was c...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445996/ https://www.ncbi.nlm.nih.gov/pubmed/26019689 http://dx.doi.org/10.1186/s12962-015-0034-z |
_version_ | 1782373356341821440 |
---|---|
author | Garris, Cindy Shah, Manan Farrelly, Eileen |
author_facet | Garris, Cindy Shah, Manan Farrelly, Eileen |
author_sort | Garris, Cindy |
collection | PubMed |
description | BACKGROUND: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder which can affect multiple organs of the body, requiring ongoing disease management and healthcare resource utilization. The economic impact of SLE has not been evaluated in a Medicare population to date. This study was conducted to assess the prevalence of SLE and its burden in terms of healthcare resource utilization and costs in a US Medicare population. METHODS: This was a retrospective observational study using Medicare medical claims data (5% random sample) for the period spanning 2003 to 2007. SLE patients were identified by having ≥2 medical claims with a primary or secondary diagnosis of ICD-9 code 710.0X. The earliest quarter of SLE diagnosis was defined as the index quarter. Prevalence of SLE, the proportion of SLE cases on disability benefits, and the contribution of SLE to new disability cases were evaluated. Healthcare resource utilization and direct medical costs (2008 US dollars) over 12 months were compared between a cohort of patients with SLE and a cohort without SLE matched on key demographics. Differences in outcomes between cohorts were assessed using McNemar’s test for dichotomous variables and paired t-tests for continuous variables. RESULTS: A total of 13,348 patients with SLE were identified. The prevalence of SLE was approximately 3 per 1000 Medicare beneficiaries. After matching, the sample consisted of 6,707 SLE and 13,414 non-SLE patients. On average, the SLE cohort compared with the non-SLE cohort had 2.4 times more physician visits, 2.7 times more hospitalizations, 2.2 times more outpatient visits, and 2.1 times more emergency room visits. A medical cost surplus of approximately $10,229 per patient per year in the SLE cohort relative to the non-SLE cohort was driven largely by inpatient hospitalization costs (p < 0.001). CONCLUSIONS: SLE prevalence was 3 per 1,000 Medicare patients. Patients with SLE consumed significantly more health care resources with significantly greater costs compared with those without SLE. Added costs were largely attributable to inpatient hospitalizations. The Medicare population is an important target for efforts to improve SLE disease management and reduce costs. |
format | Online Article Text |
id | pubmed-4445996 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44459962015-05-28 The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims Garris, Cindy Shah, Manan Farrelly, Eileen Cost Eff Resour Alloc Research BACKGROUND: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder which can affect multiple organs of the body, requiring ongoing disease management and healthcare resource utilization. The economic impact of SLE has not been evaluated in a Medicare population to date. This study was conducted to assess the prevalence of SLE and its burden in terms of healthcare resource utilization and costs in a US Medicare population. METHODS: This was a retrospective observational study using Medicare medical claims data (5% random sample) for the period spanning 2003 to 2007. SLE patients were identified by having ≥2 medical claims with a primary or secondary diagnosis of ICD-9 code 710.0X. The earliest quarter of SLE diagnosis was defined as the index quarter. Prevalence of SLE, the proportion of SLE cases on disability benefits, and the contribution of SLE to new disability cases were evaluated. Healthcare resource utilization and direct medical costs (2008 US dollars) over 12 months were compared between a cohort of patients with SLE and a cohort without SLE matched on key demographics. Differences in outcomes between cohorts were assessed using McNemar’s test for dichotomous variables and paired t-tests for continuous variables. RESULTS: A total of 13,348 patients with SLE were identified. The prevalence of SLE was approximately 3 per 1000 Medicare beneficiaries. After matching, the sample consisted of 6,707 SLE and 13,414 non-SLE patients. On average, the SLE cohort compared with the non-SLE cohort had 2.4 times more physician visits, 2.7 times more hospitalizations, 2.2 times more outpatient visits, and 2.1 times more emergency room visits. A medical cost surplus of approximately $10,229 per patient per year in the SLE cohort relative to the non-SLE cohort was driven largely by inpatient hospitalization costs (p < 0.001). CONCLUSIONS: SLE prevalence was 3 per 1,000 Medicare patients. Patients with SLE consumed significantly more health care resources with significantly greater costs compared with those without SLE. Added costs were largely attributable to inpatient hospitalizations. The Medicare population is an important target for efforts to improve SLE disease management and reduce costs. BioMed Central 2015-05-06 /pmc/articles/PMC4445996/ /pubmed/26019689 http://dx.doi.org/10.1186/s12962-015-0034-z Text en © Garris et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Garris, Cindy Shah, Manan Farrelly, Eileen The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims |
title | The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims |
title_full | The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims |
title_fullStr | The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims |
title_full_unstemmed | The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims |
title_short | The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims |
title_sort | prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445996/ https://www.ncbi.nlm.nih.gov/pubmed/26019689 http://dx.doi.org/10.1186/s12962-015-0034-z |
work_keys_str_mv | AT garriscindy theprevalenceandburdenofsystemiclupuserythematosusinamedicarepopulationretrospectiveanalysisofmedicareclaims AT shahmanan theprevalenceandburdenofsystemiclupuserythematosusinamedicarepopulationretrospectiveanalysisofmedicareclaims AT farrellyeileen theprevalenceandburdenofsystemiclupuserythematosusinamedicarepopulationretrospectiveanalysisofmedicareclaims AT garriscindy prevalenceandburdenofsystemiclupuserythematosusinamedicarepopulationretrospectiveanalysisofmedicareclaims AT shahmanan prevalenceandburdenofsystemiclupuserythematosusinamedicarepopulationretrospectiveanalysisofmedicareclaims AT farrellyeileen prevalenceandburdenofsystemiclupuserythematosusinamedicarepopulationretrospectiveanalysisofmedicareclaims |